Zosano Pharma Corporation
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zosano Pharma Corporation
Emergex CEO and ex-research director at the University of Oxford, Thomas Rademacher, spoke with Scrip about the myth of the “Wuhan virus” and why synthetic T-cell adaptive vaccines are expected to be superior to RNA/mRNA ones. More partners are being sought for additional delivery mechanisms, the founder of the UK-based, clinical-stage biotech says in this podcast interview.
Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.
Mereo will reduce its headcount by 40% to focus on its lead programs while NeuBase revealed a 60% workforce reduction to extend its cash runway. Also, Invivyd (formerly Adagio), Greenlight and BioMarin announced job cuts, while Otonomy and others planned strategic shifts.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Drug Delivery
- Other Names / Subsidiaries
- The Macroflux Company
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.